Compare Ishares Msci Italy ETF (EWI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Italy ETF vs TransMedics Group Inc — how do they compare? Ishares Msci Italy ETF trades at $60.56, while TransMedics Group Inc trades at $76.96 (market cap $2.61B). The key difference: Ishares Msci Italy ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| EWI | TMDX | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $61.14 | $150.42 |
52-Week Low | $47.75 | $61.99 |
Market Cap | — | $2.61B |
Enterprise Value | — | $3.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TransMedics (TMDX) trades at $76.89, up 3.08% today, with a bullish technical signal from moving averages. The company reported strong profitability with a 27.04% net income margin and 45.22% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in PAD Aviation aims to expand its organ transplant logistics network in Europe, enhancing its competitive position.
The outlook remains positive with a consensus price target of $108.71, representing 41% upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion investments and competitive threats. Investors should weigh strong long-term growth initiatives against near-term execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
